TABLE 2

Phospho-extracellular signal-regulated kinase (pERK) and BRAF/NRAS/MAP2K1 mutation status in the 26 analysed pulmonary Langerhans cell histiocytosis lesions

PatientCD1a cellspERK status#BRAF V600 statusMAP2K1 statusNRAS Q61 status
GenotypeMutant allele frequencyVE1GenotypeGenotypeMutant allele frequency
130+V600E36.7+WTWT0
2402+V600E20.7+WTWT0
320+V600E7.4+WTQ61K4.0
480+++V600E8.9+WTQ61K5.2
580–/+V600E29.6+WTWT0
650–/+V600E16.1+WTWT0
720++V600E9.2+WTQ61R39.1
850+V600E7.6WTWT0
920+V600E19.4+WTQ61K2.0
1010–/+V600E12.0+WTQ61R1.0
1140+V600E16.3WTWT0
1230+V600E27.9+WTQ61R1.0
1350++V600E10.5+WTQ61K8.3
1410+WT0C121SWT0
1550+WT0WTWT0
1630+/++WT0WTWT0
1750++WT0WTWT0
1830+WT0WTQ61K4.0
1940+WT0C121SWT0
2010NAWT0NAWTWT0
2120–/+WT0+WTWT0
2210NAWT0WTQ61K1.0
2310NAWT0NAWTQ61K7.9
2430+WT0C121SWT0
2510++WT0WTQ61K3.0
2630+WT0WTWT0
  • Data are presented as %, unless otherwise stated. WT: wild-type; NA: not available. #: two BRAFV600E-mutated melanomas (both positive for VE1 immunostaining) were used as positive controls (these samples were scored ++ and +++, respectively, for pERK immunostaining); : BRAF and NRAS genotyping was performed by both pyrosequencing and E-ice-COLD-PCR (enhanced improved and complete enrichment coamplification at lower denaturation temperature PCR).